Goldman Sachs analyst Salveen Richter upgraded Adaptive Biotechnologies (ADPT) to Buy from Neutral with a $9 price target Since October 2024, Adaptive has put explicit guardrails around limiting cash burn from its Immune Medicine business and made progress on initiatives to accelerate and drive sustained penetration in minimal residual disease, notes the analyst, who has become “increasingly positive” on the MRD space and believes Adaptive is well positioned to benefit from its attractive economics in the company’s niche in hematologic cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies launches assay enhancements for clonoSeq
- Adaptive Biotechnologies price target raised to $11 from $7 at Piper Sandler
- Strong Performance and Future Prospects Drive Buy Rating for Adaptive Biotechnologies
- Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank
- Stable Performance and Strategic Guidance Support Hold Rating for Adaptive Biotechnologies